Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$20.45
0.351.74%
At close: -
$20.45
0.000.00%
After Hours: May 16, 4:00 PM EDT
Comments
Loading...
Celldex Therapeutics Analyst Ratings and Price Targets | NASDAQ:CLDX | Benzinga
Celldex Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Celldex Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Goldman Sachs
Morgan Stanley
HC Wainwright & Co.
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Celldex Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | — | UBS | Trung Huynh64% | $44 → $38 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | — | Goldman Sachs | Richard Law43% | $36 → $31 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | — | Morgan Stanley | Judah Frommer65% | $46 → $43 | Maintains | Overweight | Get Alert |
| 05/09/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $50 | Maintains | Buy | Get Alert |
| 05/06/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2025 | Buy Now | — | Canaccord Genuity | Edward Nash65% | → $64 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | — | Morgan Stanley | Judah Frommer65% | → $46 | Initiates | → Overweight | Get Alert |
| 03/03/2025 | Buy Now | — | Goldman Sachs | Richard Law43% | $42 → $36 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | — | UBS | Trung Huynh64% | → $44 | Initiates | → Buy | Get Alert |
| 01/29/2025 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 01/02/2025 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 12/20/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 10/07/2024 | Buy Now | — | Citigroup | David Lebowitz52% | → $70 | Initiates | → Buy | Get Alert |
| 09/30/2024 | Buy Now | — | Goldman Sachs | Richard Law43% | → $45 | Initiates | → Neutral | Get Alert |
| 09/27/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 09/26/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | $51 → $51 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 08/12/2024 | Buy Now | — | Wells Fargo | Derek Archila56% | $35 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/12/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 07/30/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen37% | — | Initiates | → Outperform | Get Alert |
| 06/03/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | — | Guggenheim | Yatin Suneja47% | $72 → $90 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | — | TD Cowen | Yaron Werber35% | — | Initiates | → Outperform | Get Alert |
| 11/10/2023 | Buy Now | — | Wells Fargo | Derek Archila56% | → $27 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/06/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | $73 → $80 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $54 → $52 | Maintains | Overweight | Get Alert |
| 10/12/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 09/27/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | — | Wells Fargo | Derek Archila56% | → $21 | Initiates | → Underweight | Get Alert |
| 08/16/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | → $54 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska68% | $55 → $54 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | → Buy | Get Alert |
| 03/22/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | → $73 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | — | Guggenheim | Yatin Suneja47% | $68 → $63 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | — | SVB Leerink | Thomas Smith33% | $68 → $64 | Maintains | Outperform | Get Alert |
| 07/01/2022 | Buy Now | — | HC Wainwright & Co. | Joseph Hafling29% | $60 → $73 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Celldex Therapeutics (CLDX) stock?
The latest price target for Celldex Therapeutics (NASDAQ:CLDX) was reported by UBS on May 9, 2025. The analyst firm set a price target for $38.00 expecting CLDX to rise to within 12 months (a possible 85.82% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
The latest analyst rating for Celldex Therapeutics (NASDAQ:CLDX) was provided by UBS, and Celldex Therapeutics maintained their buy rating.
When was the last upgrade for Celldex Therapeutics (CLDX)?
The last upgrade for Celldex Therapeutics Inc happened on November 10, 2023 when Wells Fargo raised their price target to $27. Wells Fargo previously had an underweight for Celldex Therapeutics Inc.
When was the last downgrade for Celldex Therapeutics (CLDX)?
The last downgrade for Celldex Therapeutics Inc happened on September 27, 2024 when Wolfe Research changed their price target from N/A to N/A for Celldex Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a maintained with a price target of $44.00 to $38.00. The current price Celldex Therapeutics (CLDX) is trading at is $20.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
